Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients

Veerasarn, Vutisiri; Khorprasert, Chonlakiet; Lorvidhaya, Vicharn; Sangruchi, Supatra; Tantivatana, Thanatip; Narkwong, Ladawan; Kongthanarat, Yongyut; Chitapanarux, Imjai; Tesavibul, Chanawat; Panichevaluk, Apichart; Puribhat, Sirisak; Sangkittipaiboon, Somphob; Sookpreedee, Lak; Lertsanguansinchai, Prasert; Phromratanapongse, Pramook; Rungpoka, Poonkiat; Trithratipvikul, Supamitr; Lojanapiwat, Bannakij; Ruangdilokrat, Sathit; Ngampanprasert, Pichai

doi:10.1016/j.radonc.2004.05.007

Cited by 14 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many diseases are accompanied by long-lasting chronic inflammations with disturbed processes of immune regulation. In a number of cases, the application of WF10 improved the disease state of these patients [10][11][12][13][25][26][27][28]. Thus, our data about the inhibition of activation processes in monocytes and macrophages by WF10 coincide well with the results about clinical application of WF10.…”

Section: Discussionsupporting

confidence: 77%

“…WF10 inactivates AIDS viruses [10,23], enhances the cytotoxicity of natural killer cells [24], and prolongs cardiac graft survival in a rodent xenotransplantation model [25]. Further, the application of WF10 attenuates the disease state in radiation-associated tissue damage [12,26,27], in diabetic foot ulcera [13], and in wound healing [28,29].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of WF10 on Glycosaminoglycan Sulphation in Proinflammatory Monocytes and Macrophages

Schönberg¹,

Schlorke²,

Arnhold³

2016

Flow Cytometry - Select Topics

View full text Add to dashboard Cite

The chlorite-based drug solution WF has been successfully applied to dampen strong inflammatory disease states and to improve wound healing processes. However, the molecular mechanisms of this drug are not well understood. This study is directed to investigate how WF and its components affect the expression of surface markers and sulphated proteoglycans and glycosaminoglycans in proinflammatorystimulated monocytes and macrophages.Human blood-derived macrophages were cultivated from monocytes in the presence of U/ml granulocyte-macrophage colony-stimulating factor and activated by a mixture of ng/ml lipopolysaccharide LPS and ng/ml interferon γ IFNγ . These cells were identified and characterised by their specific cell-surface receptors CD , CD , CD , CD , CD , and CD using flow cytometry approaches. The sulphation level of proteoglycans and glycosaminoglycans was assessed by the Blyscan™ dye-binding assay. The expression of the surface marker CD , a proteoglycan with sulphated glycosaminoglycan side chains, was followed by antibodies against CD . The binding of fluorescence-labelled hyaluronan to CD was also investigated by flow cytometry. All analyses were performed after incubation of monocytes and macrophages with WF or with its main components chlorite and chlorate.The drug substance WF inhibited the activation of LPS/IFNγ-stimulated human monocyte-derived macrophages. Among them are the diminished expression of proinflammatory surface markers, the inhibition of the expression of the hyaluronan receptor CD , and the binding of hyaluronan to CD . Further, the overall amount of sulphated proteoglycans and glycosaminoglycans was down-regulated by WF . These in vitro experiments indicate that WF is able to inhibit the proinflammatory activation of macrophages. The results suggested that chlorite is the active principle in WF as chlorite caused principally the same changes in targets as WF . The WF component chlorate inhibited only the overall sulphation level of proteoglycans and glycosaminoglycans and the binding of hyaluronan to CD .

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Effects of WF10 on Glycosaminoglycan Sulphation in Proinflammatory Monocytes and Macrophages

Schönberg¹,

Schlorke²,

Arnhold³

2016

Flow Cytometry - Select Topics

View full text Add to dashboard Cite

show abstract

“…A multicentre randomised control trial showed significantly lower use of antibiotics and antispasmodics in the group treated with WF10. This study also showed a significant reduction in recurrence of haematuria one year following WF10 treatment; however, cystoscopy at one year showed objective improvement in both groups, with no significant difference [ 12 ]. Side effects include nausea, headache, and transient anaemia [ 12 , 13 ].…”

Section: Treatmentmentioning

confidence: 91%

A Narrative Review on the Pathophysiology and Management for Radiation Cystitis

Browne

Davis

Craith

et al. 2015

Advances in Urology

View full text Add to dashboard Cite

Radiation cystitis is a recognised complication of pelvic radiotherapy. Incidence of radiation cystitis ranges from 23 to 80% and the incidence of severe haematuria ranges from 5 to 8%. High quality data on management strategies for radiation cystitis is sparse. Treatment modalities are subclassified into systemic therapies, intravesical therapies, and hyperbaric oxygen and interventional procedures. Short-term cure rates range from 76 to 95% for hyperbaric oxygen therapy and interventional procedures. Adverse effects of these treatment strategies are acceptable. Ultimately, most patients require multimodal treatment for curative purposes. Large randomised trials exploring emergent management strategies are required in order to strengthen evidence-based treatment strategies. Urologists encounter radiation cystitis commonly and should be familiar with diagnostic modalities and treatment strategies.

show abstract

“…[43] WF-10, the intravenous formulation of a novel wound healing agent, tetrachlorodecaoxygen, has demonstrated some benefit in patients with wound healing disorders, including radiation cystitis. [44] It is an immune modifier and promotes wound healing through the inhibition of chronic inflammatory process. Among cervical cancer patients with grade 2 or 3 radiation cystitis, WF-10 showed a complete response rate of 74-88%.…”

Section: Etiology Of Hemorrhagic Cystitismentioning

confidence: 99%

Hemorrhagic cystitis: A challenge to the urologist

Manikandan¹,

Kumar²,

Dorairajan³

2010

Indian J Urol

110

View full text Add to dashboard Cite

Severe hemorrhagic cystitis often arises from anticancer chemotherapy or radiotherapy for pelvic malignancies. Infectious etiologies are less common causes except in immunocompromised hosts. These cases can be challenging problems for the urologist and a source of substantial morbidity and sometimes mortality for the patients. A variety of modalities of treatment have been described for the management of hemorrhagic cystitis but there is none that is uniformly effective. Some progress has been made in the understanding and management of viral hemorrhagic cystitis. This article reviews the common causes of severe hemorrhagic cystitis and the currently available management options.

show abstract

Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients

Cited by 14 publications

References 12 publications

Effects of WF10 on Glycosaminoglycan Sulphation in Proinflammatory Monocytes and Macrophages

Effects of WF10 on Glycosaminoglycan Sulphation in Proinflammatory Monocytes and Macrophages

A Narrative Review on the Pathophysiology and Management for Radiation Cystitis

Hemorrhagic cystitis: A challenge to the urologist

Contact Info

Product

Resources

About